amanqaku

IMarike yeGlobal Osteogenesis Osteogenesis Imperfecta Treatment Market, ngaMachiza ngeNdlela yoLawulo nangoMmandla: Ubungakanani, iSabelo, imbono kunye noHlahlelo lweThuba, ngo-2023 – 2030

I-Osteogenesis imperfecta sisifo sofuzo esichaphazela amathambo kwaye sithintela nomzimba ekwakheni amathambo aqinileyo.

Esi sifo senza amathambo abe brittle kwaye aphuke lula ngaphandle kwesizathu.

I-Osteogenesis Imperfecta kubhekiselwa kuyo njengokwakheka kwamathambo okungafezekanga, kwaye abantu abanengxaki yesi sifo banamathambo aphukayo okanye aphuke lula.

Introduzione

I-Osteogenesis Imperfecta yaziwa ngokuqhelekileyo njengesifo samathambo anqabileyo. Kwiimeko ezinzima, iifractures ezininzi ziqhelekileyo, ngelixa ityala elincinci libandakanya ukuphuka okumbalwa okanye amathambo aphukileyo ebomini bomntu. Abantu abanale meko bazalwa bengakwazi ukuvelisa izicubu ezixhumeneyo okanye babe nazo ngenxa yemfuza engalunganga. Ichaphazela ukuhlanganiswa kwe-collagen, iprotheni ye-tissue edibeneyo eqinisa amathambo. Esi sifo senzeka kwiifom I kunye ne-IX, kwaye mna ndinobulali kunye no-IX obulalayo. Uphawu oluphambili lwe-osteogenesis imperfecta kukuphuka rhoqo. Ezinye iimpawu ziquka ukuxengalala kwamalungu, amathambo aqhwalelayo, ukungeva kakuhle, iingxaki zokuphefumla kunye neengxaki zamazinyo. I-Osteogenesis imperfecta inokuqinisekiswa nge-DNA okanye uvavanyo lwe-collagen.

zonyango

Alukho unyango loku kuba yimeko yemfuzo. Ukuzivocavoca kunye nokuyeka ukutshaya yimizekelo emibini yokukhetha indlela yokuphila enempilo enokunceda ukukhusela i-fractures. Iibrayisi, izithomalalisi zentlungu, kunye nokhathalelo olufanelekileyo lokuqhekeka kwamathambo zonke ziluncedo. Ii-antibiotics kunye ne-antiseptics zingasetyenziselwa ukunyanga izifo zamathambo. Ukonyuka kwemfuno yonyango lwenoveli yonyango lwe-osteogenesis imperfecta kunye nezivumelwano zelayisensi kunye nentsebenziswano yobuchule ngabadlali abaphambili boshishino kuphuhliso lonyango kulindeleke ukuba kukhuthaze ukukhula kwemarike yonyango lwe-osteogenesis imperfecta kwihlabathi ngexesha lengqikelelo.

Amandla emarike

Ukonyuka kwenkxaso-mali yophando kunye nophuhliso lokuphuhlisa unyango olutsha kunye nonyango yinto ebalulekileyo ekhuthaza ukukhula kwemarike yonyango lwe-osteogenesis imperfecta yehlabathi. Ngaphaya koko, izivumelwano zeelayisenisi kunye nentsebenziswano enobuchule ngabadlali abakhulu boshishino kuphuhliso lonyango lwe-OI yenye into eqhuba ukukhula kwemarike. Ngapha koko, i-osteogenesis imperfecta sisifo sofuzo, kwaye imbali yosapho lwabantu abane-OI ibangela ukwanda kwenani lamatyala kwihlabathi liphela, ekulindeleke ukuba iqhube ukukhula kwemarike.

Umzekelo, ngoMeyi ka-2021, i-Mereo BioPharma Group plc yabhengeza idatha ekhuthazayo yeenyanga ezi-6 kwiSigaba se-II-B solingo lwezonyango kwizigulana zabantu abadala abane-osteogenesis imperfecta uhlobo IV, III okanye ndinyangelwe nge-setursumab (BPS-804). I-Arhente yaMayeza yaseYurophu (EMA) ivume isicwangciso sophando lwabantwana senkampani ye-BPS-804 kunye noyilo lokufunda lokubhalisa, kwaye umgqatswa wechiza ngoku ulungele iSigaba sesi-III kubantu babantwana.

Iimpawu eziphambili zesifundo:

Le ngxelo ibonelela ngohlalutyo olunzulu lwemakethi yehlabathi ye-Osteogenesis Imperfecta Treatment kwaye ibonelela ngobungakanani bemarike (i-USD yezigidi) kunye neNqanaba lokuKhula loNyaka (CAGR%) kwixesha loqikelelo (2023-2030), kuthathelwa ingqalelo u-2022 njengonyaka wesiseko.
Icacisa amathuba engeniso anokubakho kumacandelo ahlukeneyo kwaye icacisa isiphakamiso sotyalo-mali esinomtsalane imatrices kule marike.
Olu phononongo lukwabonelela ngolwazi oluphambili kubaqhubi beemarike, izithintelo, amathuba, ukuqaliswa kwemveliso emitsha okanye ukuvunywa, iintsingiselo zemarike, imbonakalo yengingqi, kunye nezicwangciso zokhuphiswano ezamkelwa ngabadlali abaphambili.
Iiprofayili zabadlali abaphambili kwimakethi yehlabathi ye-Osteogenesis Imperfecta Treatment esekwe kwezi parameters zilandelayo: Amagqabantshintshi eNkampani, iPotfoliyo yeMveliso, amagqabantshintshi aPhambili, ukuSebenza kwezeMali, kunye namaqhinga.
Iinkampani ezinkulu ezigutyungelwe phantsi kolu phononongo yi-BioSenic SA, i-Mereo Biopharma Group PLC, i-CELGENE CORPORATION, i-Eli Lilly kunye neNkampani, i-Cipla Inc., i-Amgen Inc., i-Sun Pharmaceutical Industries Ltd., i-Viatris Inc., i-Teva Pharmaceutical Industries Ltd. , i-Merck & Co., Inc., Jubilant Pharmova Limited, Aurobindo Pharma, Quince, Ultragenyx Pharmaceutical Inc. kunye OrthoPediatrics Corp.
Iimbono eziphuma kule ngxelo ziya kwenza ukuba abathengisi kunye nabaphathi beenkampani benze izigqibo ezifanelekileyo malunga nokuqaliswa kwemveliso kwixesha elizayo, ukuphuculwa kohlobo, ukwandiswa kweemarike kunye nobuchule bokuthengisa.

Ingxelo yemarike yehlabathi ye-Osteogenesis Imperfecta Treatment ijongana nabachaphazelekayo abohlukeneyo kweli shishini, kubandakanya abatyali-mali, ababoneleli, abavelisi beemveliso, abasasazi, abangeneli abatsha, kunye nabahlalutyi bezemali:

Abachaphazelekayo bebeya kuba lula ekwenzeni izigqibo ngokusebenzisa iimatriki zobuchule ezahlukeneyo ezisetyenziswa kuhlalutyo lwemakethi yehlabathi ye-Osteogenesis Imperfecta Treatment.